A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-08-26
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and tolerability in Japanese participants
with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D)
identified in Study 64007957MMY1001 (NCT03145181).